The company’s eGlycemic Management System ® featuring Glucommander™ has the broadest indications for use of any decision support solution for insulin titration. WALTHAM, Mass.--(BUSINESS WIRE)--The ...

A study presented at EASD 2017 shows long-term A1C reductions through personalized insulin dose adjustments every eight weeks using Glytec’s therapy management software. WALTHAM, Mass.--(BUSINESS WIRE ...

In a recent press release from Glytec, Adventist Health System, one of the largest faith-based health systems in the U.S., has partnered with Glytec, a leader in diabetes therapy management software ...

Software Offers Therapy Considerations to Help Healthcare Professionals Make More Informed Treatment Decisions MINNEAPOLIS--(BUSINESS WIRE)-- Medtronic, Inc. today announced the Food and Drug ...

FLORHAM PARK, N.J., Feb. 6, 2014 /PRNewswire/ — Managed Health Care Associates, Inc. (MHA), a leading health care services and technology company focused on alternate site health care providers, today ...

Diabetes therapy management software company Glytec has just secured its fourth FDA clearance, adding a slew of capabilities to its Glucommander product, the core of its eGlycemic Management System.

Alpine Investors has invested in Optima Healthcare Solutions. Financial terms weren’t announced. Optima’s founding team will maintain a minority stake. Palm City, Florida-based Optima is a therapy ...

Therigy, LLC, a trusted provider for specialty pharmacy therapy management software and services, announced today the release of a new proactive alert tool for financial assistance within TherigySTM.

MAITLAND, Fla., Sept. 14, 2017 /PRNewswire/ -- Therigy®, the company that pioneered patient-focused specialty therapy management in 2006, is making a subtle, yet powerful transition in its brand.

Alpine investment dates to November ’17 Potential strategic acquirers: TPG’s Mediware, ResMed’s MatrixCare, WebPT Sell-side adviser: Houlihan Lokey Alpine Investors is considering the sale of Optima ...

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group ...